Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy.

Hu YL, Jahangiri A, De Lay M, Aghi MK.

Autophagy. 2012 Jun;8(6):979-81. doi: 10.4161/auto.20232.

2.

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Rapisarda A, Melillo G.

Drug Resist Updat. 2009 Jun;12(3):74-80. doi: 10.1016/j.drup.2009.03.002. Review.

3.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

Gacche RN, Meshram RJ.

Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Review.

PMID:
24139944
4.

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK.

Cancer Res. 2012 Apr 1;72(7):1773-83. doi: 10.1158/0008-5472.CAN-11-3831.

5.

Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy.

Hu YL, Jahangiri A, Delay M, Aghi MK.

Cancer Res. 2012 Sep 1;72(17):4294-9. doi: 10.1158/0008-5472.CAN-12-1076. Review.

6.

[Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].

Cohen-Jonathan Moyal E.

Cancer Radiother. 2009 Oct;13(6-7):562-7. doi: 10.1016/j.canrad.2009.07.007. Review. French.

PMID:
19695923
7.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Review.

PMID:
20061178
8.

Autophagy, a double-edged sword in anti-angiogenesis therapy.

Liu J, Fan L, Wang H, Sun G.

Med Oncol. 2016 Jan;33(1):10. doi: 10.1007/s12032-015-0721-9. Review.

PMID:
26715036
9.

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.

McIntyre A, Harris AL.

EMBO Mol Med. 2015 Feb 19;7(4):368-79. doi: 10.15252/emmm.201404271. Review.

10.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Review.

PMID:
18948057
11.

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.

Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB.

Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003.

PMID:
18805433
12.

The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.

Rüegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R.

Curr Mol Med. 2003 Dec;3(8):673-91. Review.

PMID:
14682490
13.

Metabolic effects of anti-angiogenic therapy in tumors.

Zulato E, Curtarello M, Nardo G, Indraccolo S.

Biochimie. 2012 Apr;94(4):925-31. doi: 10.1016/j.biochi.2012.01.001. Review.

PMID:
22245704
14.

Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis.

Yang J, Chen S, Huang X, Han J, Wang Q, Shi D, Cheng R, Gao G, Yang X.

Cancer Biol Ther. 2010 Jun 15;9(12):967-74.

PMID:
20364117
15.

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J.

Cancer Metastasis Rev. 2001;20(1-2):79-86. Review.

PMID:
11831651
16.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

17.

Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.

Sato Y.

Int J Clin Oncol. 2003 Aug;8(4):200-6. Review.

PMID:
12955574
18.

Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch.

Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A, Métivier D, Bidart JM, Germain S, Perricaudet M, Schlumberger M.

J Clin Invest. 2007 Jul;117(7):1844-55.

19.

Wondonin, a novel compound, inhibits hypoxia-induced angiogenesis through hypoxia-inducible factor 1 alpha.

Jun HO, Kim Y, Kwon YW, Hong SS, Kim KW, Shin J, Kim TY.

FEBS Lett. 2007 Oct 16;581(25):4977-82.

20.

Hypoxia: a key regulator of angiogenesis in cancer.

Liao D, Johnson RS.

Cancer Metastasis Rev. 2007 Jun;26(2):281-90. Review.

PMID:
17603752
Items per page

Supplemental Content

Support Center